- Business08 April 2022
As we continue to deliver on our brand promise of being the preferred partner and setting a new standard for the future of Pharma, Adalvo provides various solutions and differentiated...
- Business05 April 2022
Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked and the submission will be completed in July 2022.
- Business29 March 2022
We are pleased to announce that we have now completed our Pivotal BE program for Apremilast Film-Coated Tablets. This product has been developed in collaboration with one of our strategic...
- Business23 March 2022
We are pleased to provide a status update on our development of Eribulin injection 0.44mg/ml. The development of this product is progressing very well; our dossier will be available for...
- Business17 March 2022
We are pleased to announce that, following the successful completion of our ANDA for Midostaurin Capsules 25mg in the US, we have now completed our Pivotal BE program in Europe....
- Business15 March 2022
We are pleased to announce that our US dossier of Semaglutide 1.34mg/ml pre-filled pen is ready and available for licensing in Ex-US markets. We will now move full steam...
- Business09 March 2022
Adalvo announces commencement of DCP procedure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablet
Adalvo is delighted to announce that we have successfully completed dossier filing of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With the present submission, we believe we will be amongst...
- Business28 February 2022
Aztiq partners with SK Pharma to create Arphio, a new business entity dedicated solely to orphan and rare disease medicines
Aztiq is thrilled to announce the recent establishment of a new entity Arphio a venture initiated in close collaboration with SK Pharma.
- Business22 February 2022
Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Apixaban 5mg Film Coated Tablets.
- Business17 February 2022
CellResearch Corporation (CRC) has been awarded SME Designation by the European Medicines Agency (EMA)
Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), a clinical stage company developing innovative stem cell therapies, announced today that the European Commission and the European Medicines...
- Business27 January 2022
Adalvo is pleased to announce that we have successfully launched Icatibant in 14 markets. This product is a complex injectable peptide, forming part of our high-value product portfolio offering to...
- Business05 January 2022
As this new year begins, Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Vortioxetine Film-Coated Tablets.
- Business07 December 2021
Adalvo is thrilled to announce that we have entered into a strategic collaboration deal with Naari Pharma, a vertically integrated women’s health pharmaceutical business, based in Bangalore, India.
- Business02 December 2021
Adalvo is pleased to announce that we have successfully submitted our EU DCP procedure for Nitrofurantoin ER 100mg Capsules, another differentiated product within our portfolio, that was developed based on...
- Business26 November 2021
Adalvo, one of the leading B2B global pharmaceutical companies, with commercial partnerships in more than 100 countries, have been certified as one of the Best Places to Work for 2021!...
- Business26 November 2021
The Consortium jointly, through Aztiq II HoldCo Limited, will acquire a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus and Adalvo.
- Business15 November 2021
We are pleased to announce that our General Manager, Anil Okay has been awarded the Leader of the Year Award 2021, by the Global Generics & Biosimilar Awards committee.
- Business11 November 2021
Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Nintedanib 100mg & 150mg soft gel capsules. We are now moving ahead into dossier completion, and...
- Business08 November 2021
Adalvo announces successful Pivotal BE outcome of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablet
Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. We are now moving ahead into dossier completion and...
- Business04 November 2021
We are proud to announce the successful submission of our DCP procedure for our distinguished hybrid / 505(b)(2) asset Gralise®. We expect to launch this high- value asset in H1...
- Business02 November 2021
We are extremely delighted to announce that we successfully submitted our DCP procedure for Liraglutide 6mg/ml pre-filled pen on Friday 29th October, which has been developed in close...